BiotechTube
Maxim Biomedical

Maxim Biomedical

Frederick, United States· Est.
maximbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $23M

Overview

MaximBio is a leading US-based CDMO focused on lateral flow assay (LFA) and immunoassay development and manufacturing. With over 20 years of experience, the company has established itself as a trusted partner for complex diagnostic programs, including high-volume pandemic response tests and Class III/BLA-regulated products. Its integrated model combines deep R&D expertise with scalable, compliant manufacturing, positioning it as a critical domestic supplier for public health, commercial, and government diagnostic needs.

Diagnostics

Technology Platform

Integrated development and manufacturing platform for lateral flow assays (LFA), ELISA, and custom immunoassays. Capabilities include antibody screening/conjugation, reagent formulation, product design, prototyping, and scalable GMP production.

Funding History

2
Total raised:$23M
Series A$20M
Seed$3M

Opportunities

Strong demand for US-based diagnostic manufacturing due to supply chain reshoring trends and public health preparedness needs.
Growth in over-the-counter and home-use diagnostics expands the addressable market for lateral flow assays.
The company's proven track record with complex, Class III diagnostics positions it well for high-value partnerships.

Risk Factors

Revenue dependency on a limited number of large government or pharmaceutical contracts.
Intense regulatory scrutiny in diagnostics manufacturing poses compliance risks.
Long-term technological disruption from emerging diagnostic platforms could challenge the dominance of lateral flow assays.

Competitive Landscape

Competes with other diagnostic CDMOs like Meridian Bioscience, Bio-Techne, and OraSure, as well as large in-house manufacturing arms of major diagnostics companies. Differentiation is achieved through deep, integrated US-based services, a strong regulatory track record, and proven scale in high-volume production, particularly for government and emergency response.

More companies in United States →